Dermata Therapeutics, Inc. Common Stock (DRMA) is a publicly traded Healthcare sector company. As of May 21, 2026, DRMA trades at $1.22 with a market cap of $4.83M and a P/E ratio of -0.15. DRMA moved +0.00% today. Year to date, DRMA is -43.18%; over the trailing twelve months it is -84.53%. Its 52-week range spans $1.10 to $23.70. Analyst consensus is buy with an average price target of $4.00. Rallies surfaces DRMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Dermata Sets Mid-2026 Launch of Weekly Skincare Mask, Secures $2M ATM Funding: Dermata Therapeutics launched its new direct-to-consumer skincare brand Tome and plans a mid-2026 debut of its once-weekly Tome Foundational Treatment while hiring a VP of Marketing. The company raised $2.0 million net in Q1 ATM financing, holds $6.9 million cash, and expects runway into Q1 2027.
| Metric | Value |
|---|---|
| Price | $1.22 |
| Market Cap | $4.83M |
| P/E Ratio | -0.15 |
| EPS | $-8.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $23.70 |
| 52-Week Low | $1.10 |
| Volume | 148 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-7.56M |
| Gross Margin | 0.00% |
1 analysts cover DRMA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.00.